4-氯喹啉-8-羧酸 | 216257-37-3

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯喹啉-8-羧酸
• 英文名称: 4-chloroquinoline-8-carboxylic acid
• 英文别名: 4-chloro-8-quinolinecarboxylic acid
• CAS: 216257-37-3
• 化学式: C₁₀H₆ClNO₂
• 分子量: 207.616
• InChiKey: QLGATRTYRGPJDU-UHFFFAOYSA-N

物化性质

• 沸点：
  399.1±22.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氯喹啉-8-羧酸 、 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1-(4-methyl-4-piperidinyl)-piperidine 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 生成 8-[[4-[4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1-piperidinyl]-4-methyl-1-piperidinyl]carbonyl]-4-chloroquinoline
  参考文献：
  名称：

  [EN] QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS
  [FR] DERIVES DE QUINOLYLE AMIDE ANTAGONISTES DE CCR-5

  摘要：

  本发明涉及一系列化合物，其为一般式(I)的CCR-5受体拮抗剂，或其药学上可接受的盐，其中变量在此处定义。

  公开号：

  WO2004113323A1

文献信息

• [EN] TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS.<br/>[FR] DÉRIVÉS DE TRIAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA TANKYRASE
  申请人：GOLDING LOUISE

  公开号：WO2022008896A1

  公开（公告）日：2022-01-13

  The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R' )2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(0)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R')2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from -OH, -N(R3)2, -SO2N(R3)2 and -C(O)N(R4)2, preferably by at least one substituent selected from -OH, -SO2N(R3)2 and -C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

  本发明涉及一般式(I)的化合物、互变异构体、立体异构体、N-氧化物、药学上可接受的盐及其前药，以及制备这些化合物的方法、含有这些化合物的制剂的制备方法以及它们在治疗中的应用：其中：虚线表示可选键；X表示：一个5-或6-成员的不饱和杂环基，可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、-NO2、-N（R）2和-SO2R（其中每个R独立地为H或C1-6烷基，例如H或C1-3烷基）；一个可选地被一个或多个（例如1或2个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的C3-5环烷基；或一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的芳基基团；Y表示：一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的芳基或杂环芳基基团；一个可选地被一个或多个（例如1、2或3个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的5-或6-成员饱和杂环基；或一个可选地被一个或多个（例如1或2个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的C3-6环烷基；Z表示：一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、- 、-OH、-N（R'）2（其中每个R1独立地为H或C1-6烷基，例如H或C1-3烷基）、-SO2R2（其中R2为H或C1-6烷基，例如H或C1-3烷基）、-SO2N（R3）2（其中每个R3独立地为H或C1-6烷基，例如H或C1-3烷基）和-C（0）N（R4）2（其中每个R4独立地为H或C1-6烷基，例如H或C1-3烷基，或其中两个R4基与介于其间的氮原子一起形成3到6成员的饱和杂环环）；或一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、- 、-OH、-N（R'）2（其中每个R1独立地为H或C1-6烷基，例如H或C1-3烷基）、-SO2R2（其中R2为H或C1-6烷基，例如H或C1-3烷基）、-SO2N（R3）2（其中每个R3独立地为H或C1-6烷基，例如H或C1-3烷基）和-C（O）N（R4）2（其中每个R4独立地为H或C1-6烷基，例如H或C1-3烷基，或其中两个R4基与介于其间的氮原子一起形成3到6成员的饱和杂环环）的不饱和的5-到10-成员的单环或双环杂环基；但是，当化合物不是式(I)的N-氧化物时，Z必须被至少一个取代基取代，所述取代基选自-OH、-N（R3）2、-SO2N（R3）2和-C（O）N（R4）2，优选地被至少一个取代基选自-OH、-SO2N（R3）2和-C（O）N（R4）2。这些化合物在治疗和/或预防对坦克酰酶1和/或2的抑制有反应的疾病或障碍中特别有用，例如由坦克酰酶1和/或2介导的癌症。
• Quinolyl amide derivatives as CCR-5 antagonists
  申请人：Lu Shou-Fu

  公开号：US20050020605A1

  公开（公告）日：2005-01-27

  The present invention relates to a series of compounds which are CCR-5 receptor antagonists of the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.

  本发明涉及一系列通式I的CCR-5受体拮抗剂化合物，或其药学上可接受的盐，其中变量在此定义。
• QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS
  申请人：Schering Aktiengesellschaft

  公开号：EP1633737A1

  公开（公告）日：2006-03-15
• [EN] NEW AMINOALCOHOL DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'AMINOALCOOL
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002000622A2

  公开（公告）日：2002-01-03

  The present invention relates to a compound of formula (I): wherein X1 is bond or -OCH2-; X2 is -(CH2)n-, in which n is 1 or 2; X3 is bond, -O- or -NH-; R1 is phenyl, indolyl or carbazolyl, each of which is optionally substituted with one or two substituent(s) selected from the group consisting of hydroxy, halogen, nitro, amino, formyl, (lower)alkylsulfonylamino, aryl(lower)alkoxy and hydroxy(lower)alkyl; R2 is hydrogen or aryl(lower)alkyl; R3 is hydrogen or hydroxy(lower)alkyl; R4 is aryl, 4-quinolyl, phthalazinyl, quinazolinyl, cinnolinyl or naphthyridinyl, each of which is optionally substituted with one or two substituent(s) defined in the specification, or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.